ArticleLeukemia2015
Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group.
Abstract readLetter
In one paragraph
Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular Landscape of Acute Myeloid Leukemia in Pediatric Patient-Age-Related Correlations: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant.Pediatric blood & cancer · 2026Article
- Altered Expression of NK Receptors in Racially/Ethnically Diverse and Risk-of-Relapse Pediatric Acute Lymphoblastic Leukemia Patients.Biomedicines · 2025Article
- Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML.Blood advances · 2023Article
- [Analysis of clinical significance and prognostic impact of TET2 single nucleotide polymorphism I1762V in patients with acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- A rare case of acute promyelocytic leukemia with ider(17)(q10)t(15;17)(q22;q21) and favorable outcome.Molecular cytogenetics · 2020Article
- The Prognostic Significance of TET2 Single Nucleotide Polymorphism in Egyptian Chronic Myeloid Leukemia.Mediterranean journal of hematology and infectious diseases · 2020Article
- TET2 Single Nucleotide Polymorphism in Myeloid Neoplasms Among Egyptian Patients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020Article
- Review
- Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression.Oncotarget · 2017Article
- Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.Frontiers in pharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
M A KutnyDepartment of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
T A AlonzoDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
E R GamazonDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
R B GerbingChildren's Oncology Group, Monrovia, CA, USA.
D GeraghtyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
B LangeOncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
N A HeeremaDepartment of Pathology, The Ohio State University, Columbus, OH, USA.
L SungThe Division of Haematology/Oncology and Child Health Evaluative Sciences, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
R AplencOncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
J FranklinAmgen, Inc, Thousand Oaks, CA, USA.
S C RaimondiDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
B A HirschDivision of Laboratory Medicine, University of Minnesota Medical Center-Fairview, Minneapolis, MN, USA.
A KonkashbaevDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
N J CoxDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
K OnelDepartment of Pediatrics, The University of Chicago, Chicago, IL, USA.
A S GamisDivision of Hematology/Oncology, Children's Mercy Hospital and Clinics, Kansas City, MO, USA.
S MeshinchiClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5MTowards a preventive cancer vaccine for children with constitutional mismatch repair deficiencyUG1CA189955 · NCI · PUBLIC HEALTH INSTITUTE · PI BRAD H POLLOCK, Michael E. Roth · 2014 to 2026
$62.5MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MPEDIATRIC ONCOLOGY RESEARCH TRAINING PROGRAMT32CA009351 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth R Lawlor, SOHEIL MESHINCHI · 1985 to 2026
$7.0MBiology/prognostic implications of Flt3 mutations in AMLR01CA114563 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MESHINCHI, SOHEIL · 2005 to 2016
$4.4MAccurate Prediction of Acute Myeloid Leukemia RelapseR21CA104964 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MESHINCHI, SOHEIL · 2004 to 2005
$311kNCI NIH HHS R01 CA114563NCI NIH HHS R01-CA114563NCI NIH HHS R21 CA104964NCI NIH HHS R21-CA104964-02NCI NIH HHS T32 CA009351NCI NIH HHS T32CA009351NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U10-CA98413NCI NIH HHS U10-CA98543NCI NIH HHS U24 CA114766NCI NIH HHS U24-CA114766NCI NIH HHS UG1 CA189955
Abstract
PubMed holds no abstract for this paper.
Indexed as
Polymorphism, Single NucleotideChildDioxygenasesDNA-Binding ProteinsGenotypeHumansLeukemia, Myeloid, AcuteProto-Oncogene ProteinsQuantitative Trait LociDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.